{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T17:27:11Z","timestamp":1770571631915,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1111\/dsu.12073","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T04:19:54Z","timestamp":1357791594000},"page":"165-170","source":"Crossref","is-referenced-by-count":9,"title":["A New Botulinum Toxin Potentially Bioequivalent to OnabotulinumtoxinA: Are There Any Differences at All?"],"prefix":"10.1097","volume":"39","author":[{"given":"Gi-Hyeok","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Ho","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"4","key":"R1-4-20210206","first-page":"253","article-title":"Clostridium botulinum toxin.","volume":"16","author":"Oguma","year":"1997","journal-title":"Toxin Rev"},{"issue":"7","key":"R2-4-20210206","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"R4-4-20210206","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-2005-915441","article-title":"Xeomin: perspektiven einer neuen therapeutischen Botulinumtoxinpraparation.","volume":"33","author":"Dressler","year":"2006","journal-title":"Aktuelle Neurologie"},{"issue":"10","key":"R5-4-20210206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s004150070100","article-title":"Complete secondary botulinum toxin therapy failure in blepharospasm.","volume":"247","author":"Dressler","year":"2000","journal-title":"J Neurol"},{"issue":"6","key":"R6-4-20210206","first-page":"1","article-title":"Botulinum toxin products overview.","volume":"13","author":"Carruthers","year":"2008","journal-title":"Skin Therapy Lett"},{"key":"R8-4-20210206","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-1119(03)00792-3","article-title":"Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type AHall (Allergan) strain.","volume":"315","author":"Zhang","year":"2003","journal-title":"Gene"},{"issue":"4","key":"R9-4-20210206","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2710.2007.00835.x","article-title":"Comparing two botulinum toxin type A formulations using manufacturers product summaries.","volume":"32","author":"Wenzel","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R10-4-20210206","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"issue":"7-8","key":"R12-4-20210206","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10930-008-9151-2","article-title":"Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis.","volume":"27","author":"Lietzow","year":"2008","journal-title":"Protein J"},{"issue":"1","key":"R14-4-20210206","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/exnr.2000.7583","article-title":"Botulinum A toxin: Dysport improvement of biological availability.","volume":"168","author":"Bigalke","year":"2001","journal-title":"Exp Neurol"},{"issue":"4","key":"R15-4-20210206","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.biologicals.2003.08.001","article-title":"Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin.","volume":"31","author":"Sesardic","year":"2003","journal-title":"Biologicals"},{"issue":"1","key":"R16-4-20210206","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/taap.1994.1181","article-title":"Measurement of botulinum toxin activity: evaluation of the lethality assay.","volume":"128","author":"Pearce","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"R17-4-20210206","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.toxicon.2009.06.020","article-title":"Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats.","volume":"54","author":"Sakamoto","year":"2009","journal-title":"Toxicon"},{"key":"R18-4-20210206","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.toxicon.2009.09.005","article-title":"Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins.","volume":"3","author":"Torii","year":"2010","journal-title":"Toxicon"},{"issue":"12","key":"R19-4-20210206","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0041-0101(01)00101-5","article-title":"A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.","volume":"39","author":"Aoki","year":"2001","journal-title":"Toxicon"},{"issue":"7","key":"R20-4-20210206","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0041-0101(02)00086-7","article-title":"Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.","volume":"40","author":"Aoki","year":"2002","journal-title":"Toxicon"},{"issue":"12","key":"R21-4-20210206","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/jor.20450","article-title":"Effects of Botox and Neuronox on muscle force generation in mice.","volume":"25","author":"Stone","year":"2007","journal-title":"J Orthop Res"},{"issue":"5","key":"R22-4-20210206","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/NRL.0b013e31816f2cdd","article-title":"Clinical comparisons of botulinum neurotoxin formulations.","volume":"14","author":"Brashear","year":"2008","journal-title":"Neurologist"},{"issue":"Suppl 8","key":"R23-4-20210206","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/mds.20066","article-title":"Clinical comparability of marketed formulations of botulinum toxin.","volume":"19","author":"Sampaio","year":"2004","journal-title":"Mov Disord"},{"issue":"7","key":"R24-4-20210206","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00702-004-0234-8","article-title":"Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers.","volume":"112","author":"Jost","year":"2005","journal-title":"J Neural Transm"},{"issue":"1","key":"R25-4-20210206","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e3181692735","article-title":"Potency evaluation of a formulated drug product containing 150kd botulinum neurotoxin type A.","volume":"32","author":"Hunt","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"R26-4-20210206","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.WNF.0000240951.18821.50","article-title":"Neurophysiological doubleblind trial of a botulinum neurotoxin type a free of complexing proteins.","volume":"30","author":"Wohlfarth","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"R27-4-20210206","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3341\/kjo.2009.23.3.137","article-title":"Doubleblind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.","volume":"23","author":"Yoon","year":"2009","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"R28-4-20210206","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1469-8749.2010.03830.x","article-title":"Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, doubleblinded, controlled multicentre clinical trial.","volume":"53","author":"Kim","year":"2011","journal-title":"Dev Med Child Neurol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042728-201301020-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:42:17Z","timestamp":1618278137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201301020-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1111\/dsu.12073","relation":{},"ISSN":["1076-0512"],"issn-type":[{"value":"1076-0512","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}